CAMBRIDGE, England--(BUSINESS WIRE)--Adrestia Therapeutics, a leader in synthetic rescue therapies for genetic diseases, today announced its co-founder, Professor Steve Jackson FRS FMedSci, has been named a Knight Bachelor in the 2023 Birthday Honours List, which announces the bestowing of various awards and designations on the King’s Birthday in the United Kingdom. Professor Jackson is a noted scientist-entrepreneur and holds several academic positions in addition to being the Chief Scientific Officer of Adrestia. The Knights Bachelor are appointed by the British sovereign and have existed as an order since the Middle Ages.
Adrestia Therapeutics Partners with Leading Patient Advocacy Groups to Form Ataxia Telangiectasia Research Consortium
MARTINSRIED, Germany and Munich, Germany, Oct. 25, 2022 (GLOBE NEWSWIRE) -- Proteros biostructures GmbH (“Proteros”) today announced that it has initiated a multi-target drug discovery partnership with Adrestia Therapeutics (Cambridge, UK), a leader in synthetic rescue therapies for genetic diseases. Proteros will provide access to its entire customizable platform of technologies for early drug discovery guided by the company’s experienced discovery teams.
CAMBRIDGE, England--(BUSINESS WIRE)--Adrestia Therapeutics, a leader in synthetic rescue therapies for genetic diseases, today announced the appointment of Dr James Osborne as Head of Chemistry and the initiation of a multi-target partnership with Proteros biostructures GmbH (Munich, Germany) to accelerate the discovery of first-in-class candidate drugs for intractable diseases.
CAMBRIDGE, England--(BUSINESS WIRE)--Adrestia Therapeutics, a leader in synthetic rescue therapies for genetic diseases, today announced that it appointed William H. Lewis, J.D., M.B.A. as Chair of its Board of Directors, Jennifer Millian, M.S., M.B.A. as VP of U.S. Operations, and Philip Coxon, Ph.D., as VP of Business Development. This extends Adrestia’s presence to the United States and deepens its drug development capabilities as it moves its emerging pipeline of first-in-class therapeutics towards the clinic.
CAMBRIDGE, England--(BUSINESS WIRE)--Adrestia Therapeutics, a leader in synthetic rescue therapies for genetic diseases, today announced the appointment of Professor John R.B. Perry as its Vice President, Human Genetics. Dr Perry is a world-renowned expert in human population genetics at the University of Cambridge with a track record of identifying genetic drivers of complex, multigenic diseases and health-related traits. His expertise will complement Adrestia’s technology platform, which is already progressing a series of first-in-class therapies to treat both rare and common diseases with a genetic component.